Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development

Oragenics, Inc., a biotechnology company developing intranasal therapeutics for brain-related conditions, announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry-leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion.

This agreement is expected to ensure Good Manufacturing Practice (GMP)-compliant drug product supply ahead of the planned Phase IIb clinical trials which the Company expects to start next year. The collaboration marks an important milestone for Oragenics as it secures domestic production capabilities to support its upcoming clinical and regulatory efforts.

Read more about Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development.